Skip to main content

Advertisement

SpringerLink
Log in

Spironolactone in the treatment of central serous chorioretinopathy – a case series

  • Medical Ophthalmology
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

The pathogenesis of central serous chorioretinopathy (CSC) is still poorly understood. An animal model of CSC proved that the mineralocorticoid receptor [1] of the choroid also plays a role in CSC. Since there is still no evidence-based therapy for non-self-limiting CSC, this case series evaluates the effect of oral spironolactone in CSC patients.

Methods

In this interventional, uncontrolled, prospective case series, we present 18 consecutive CSC patients. Patients were treated with spironolactone 25 mg twice daily (Spironolacton AL® 50 mg, ALIUD PHARMA) for up to 12 weeks. Follow–up examinations with BCVA, OCT, and EDI-OCT were performed at 1, 2, and 3 months after starting the treatment. Main outcome measure was a change of subretinal fluid (SRF) (in micrometers) measured by optical coherence tomography. Secondary outcome was a change in central retinal thickness (CRT) (in micrometers) measured by OCT and a change in BCVA.

Results

The subretinal fluid (SRF; mean) decreased from 219 μm (baseline) to 100 μm (visit 3) (difference 119 μm). Total central retinal thickness (CRT; mean) decreased from 405 μm before treatment (baseline) to 287 μm after treatment (difference 118 μm). The BCVA (in logMAR; mean) increased from 0.32 at baseline to 0.20 at visit 3.

Conclusion

Our case series could confirm a positive influence of spironolactone on the course CSC. Longer follow-up with a larger number of cases could provide more data about the long-term efficiency, recurrences, and safety of this well-tolerated and non-invasive treatment option of CSC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122(7):2672–2679. doi:10.1172/jci61427

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115(1):169–173. doi:10.1016/j.ophtha.2007.02.032

    Article  PubMed  Google Scholar 

  3. Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68(11):815–820. doi:10.1136/bjo.68.11.815

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29(10):1469–1473. doi:10.1097/IAE.0b013e3181be0a83

    Article  PubMed  Google Scholar 

  5. Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16(3):203–213

    Article  CAS  PubMed  Google Scholar 

  6. Steinle NC, Gupta N, Yuan A, Singh RP (2012) Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol 96(1):10–13. doi:10.1136/bjophthalmol-2011-300183

    Article  PubMed  Google Scholar 

  7. Roisman L, Magalhaes FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, Farah ME (2013) Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging 44(5):465–470. doi:10.3928/23258160-20130909-08

    Article  Google Scholar 

  8. Beger I, Koss MJ, Koch F (2012) Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab. Ophthalmologe 109(12):1224–1232. doi:10.1007/s00347-012-2688-7

    Article  CAS  PubMed  Google Scholar 

  9. Behnia M, Khabazkhoob M, Aliakbari S, Abadi AE, Hashemi H, Pourvahidi P (2013) Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy. Retina 33(2):324–328. doi:10.1097/IAE.0b013e3182670fa3

    Article  PubMed  Google Scholar 

  10. Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF (2014) Collaborative Retrospective Macula Society Study of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Ophthalmology. doi:10.1016/j.ophtha.2013.11.040

    Google Scholar 

  11. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33(10):2096–2102. doi:10.1097/IAE.0b013e318297a07a

    Article  CAS  PubMed  Google Scholar 

  12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure randomized aldactone evaluation study investigators. N Engl J Med 341(10):709–717. doi:10.1056/nejm199909023411001

    Article  CAS  PubMed  Google Scholar 

  13. Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41(2):201–214. doi:10.1111/j.1442-9071.2012.02848.x

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Eye Hospital – LMU, Campus Innenstadt, Klinikum der Universität München, Mathildenstrasse 8, D-80336, Munich, Germany

    T. R. Herold, K. Prause, A. Wolf, W. J. Mayer & M. W. Ulbig

Authors
  1. T. R. Herold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Prause
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. J. Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. W. Ulbig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. R. Herold.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herold, T.R., Prause, K., Wolf, A. et al. Spironolactone in the treatment of central serous chorioretinopathy – a case series. Graefes Arch Clin Exp Ophthalmol 252, 1985–1991 (2014). https://doi.org/10.1007/s00417-014-2780-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-014-2780-6

Keywords

Search

Navigation